FierceBiotech

Novartis hits the cGAS, taking option to buy IFM unit for $90M upfront

Novartis is stepping on the cGAS. Three years after securing an option on an IFM Therapeutics subsidiary, the Swiss drugmaker has accelerated into the deal and paid $90 million upfront for small ...
FierceBiotech

Novartis bankrolls IFM Due's cGAS/STING pipeline—with $840M buyout option

Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary ...
Nasdaq

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System

Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...
Bloomberg L.P.

Australia’s IFM Investors to Wind Down Private Equity Unit

Australian investment manager IFM Investors will wind down its domestic private equity unit in coming years, citing a lack of scale to make it commercially viable and a focus on other global ...